In experimental models, a MR blocker reduces albuminuria, glomerulosclerosis, renal macrophage infiltration, renal monocyte chemoattractant protein 1 (MCP-1) synthesis, and expression of MCP-1′s upstream transcription factor NF-κB[33]. The gene discussed is CCL2; the disease is glomerulosclerosis.